Codexis, Inc. (NASDAQ: CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, announces the filing of a lawsuit against EnzymeWorks and its founder, Junhua “Alex” Tao, for willful patent infringement, misappropriation of trade secrets, breach of confidence, and other claims. The suit was filed as Case No. 3:16-cv-00826-BLF in the United States District Court, Northern District of California on February 19, 2016.
Codexis, Inc. (NASDAQ:CDXS) belongs to Healthcare sector. Its net profit margin is -11.90% and weekly performance is -0.73%. On last trading day company shares ended up at $4.07.
Radius Health, Inc. (NASDAQ:RDUS) reported a net loss of $33.2 million, or $0.77 per share, as compared to a net loss of $18.0 million, or $0.55 per share for the three months ended December 31, 2014. The increase in net loss for the three months ended December 31, 2015 as compared to the three months ended December 31, 2014 was primarily due to an increase in research and development and general and administrative expenses, partially offset by a decrease in interest expense.
Radius Health, Inc. (NASDAQ:RDUS) shares decreased -2.98% in last trading session and ended the day at $30.00. RDUS return on assets is -31.70%. Radius Health, Inc. (NASDAQ:RDUS) quarterly performance is -51.05%.
On 19 February, Telephone and Data Systems, Inc. (NYSE:TDS) reported total operating revenues of $1,274.5 million for the fourth quarter of 2015, versus $1,297.1 million for the comparable period one year ago. Net loss attributable to TDS shareholders and related diluted earnings per share improved to $0.8 million and $0.01, respectively, for the fourth quarter of 2015, compared to $16.6 million and $0.15, respectively, in the comparable period one year ago.
On 26 February, Telephone & Data Systems Inc. (NYSE:TDS) shares increased 1.11% and was closed at $26.38. TDS EPS growth in last 5 year was -23.10%. Telephone & Data Systems Inc. (NYSE:TDS) year to date (YTD) performance is 1.89%.
Stamps.com (NASDAQ: STMP) reported Q4 EPS of $1.57, $0.63 better than the analyst estimate of $0.94. Revenue for the quarter came in at $69.9 million versus the consensus estimate of $57.96 million. GUIDANCE: Stamps.com sees FY2016 EPS of $5.00-$5.50, versus the consensus of $4.38. Stamps.com sees FY2016 revenue of $290-310 million, versus the consensus of $278.1 million.
Stamps.com Inc. (NASDAQ:STMP) ended the last trading day at $116.51. Company weekly volatility is calculated as 5.14% and price to cash ratio as 0.89. Stamps.com Inc. (NASDAQ:STMP) showed a weekly performance of 22.66%.
Peregrine Pharmaceuticals (NASDAQ: PPHM) announced that it is discontinuing the companys Phase III SUNRISE trial of bavituximab in patients with previously treated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC). The decision to stop the trial was based on the recommendation of the study’s Independent Data Monitoring Committee (IDMC) following a pre-specified interim analysis performed after 33% of targeted overall events (patient deaths) in the study were reached.
Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) shares decreased -61.86% in last trading session and ended the day at $0.41. PPHM Gross Margin is 49.70% and its return on assets is -59.70%. Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) quarterly performance is -66.55%.